Riskpilot← Back to searchSign inGet full accessCuraCell TX AB
ABActiveOrg 5592808546Nanna Svartz Väg 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 20205 employees
Revenue 2025
SEK 45K
-97% vs 2024
EBITDA margin
-70916.3%
-330% vs 2024
Equity ratio
13.8%
Financial strength
Net profit 2025
SEK -32,1M
-351% vs 2024
| Revenue | SEK 45K | -97% |
| EBITDA | SEK -31,9M | -330% |
| Net profit | SEK -32,1M | -351% |
| Total assets | SEK 49,4M | +32% |
| Equity | SEK 6,8M | -76% |
| Employees | 5 | — |
Legal name
CuraCell TX AB
Org number
5592808546
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3 november 2020
Share capital
SEK 1 802 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Utveckla teknologier och metoder inom området immunonkologi. Utvecklingen kan ske i egen regi, via dotterbolag eller genom licens- och samarbetsavtal.
Address
Nanna Svartz Väg 4
Email
hakan.hallberg@takura.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 367 | 45 |
| Staff expenses | — | — | −378 | −3 163 | −5 450 |
| EBITDA | −6 | −675 | −5 304 | −7 413 | −31 912 |
| Depreciation & amort. | −0 | — | −9 | −74 | −152 |
| EBIT | −6 | −675 | −5 313 | −7 487 | −32 064 |
| Net financials | −2 | — | −0 | 375 | −2 |
| Profit before tax | −8 | −675 | −5 313 | −7 112 | −32 065 |
| Tax | −0 | — | — | — | — |
| Net profit | −8 | −675 | −5 313 | −7 112 | −32 065 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 11 996 | 29 679 | 31 689 | 37 334 | 49 388 |
| Equity | 2 017 | 1 342 | 26 029 | 28 892 | 6 831 |
| Long-term debt | 0 | 28 051 | 4 439 | 6 982 | 39 079 |
| Short-term debt | 9 979 | 286 | 1 221 | 1 460 | 3 478 |
| Total debt | 9 979 | 28 337 | 5 660 | 8 442 | 42 556 |
EBITDA margin
-70916.3%
This company
15.8%
Market median
-448937% vs market
20212025
Equity ratio
13.8%
This company
38.2%
Market median
-64% vs market
20212025
Return on equity
-469.4%
This company
18.4%
Market median
-2651% vs market
20212025
Net profit margin
-71256.5%
This company
8.1%
Market median
-879810% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
6.23×
This company
0.62×
Market median
-905% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PJ Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Takura AB | Company | 93.0% | 93.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Takura AB
CuraCell TX AB (this company)Curacell Germany GmbhPolybiocept GmbhCURACELL GERMANY GMBHPOLYBIOCEPT GMBHBoard members of CuraCell TX AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Jonas Båtelson | Chief Executive Officer | 0 companies |
| Per Gunnar Båtelson | Deputy Board Member | 0 companies |
| Håkan Thore Hallberg | Board of Directors | 0 companies |
| Thomas Schlegel | Board of Directors | 0 companies |